Aduro announces acquisition of GVAX assets from BioSante Aduro BioTech announces the acquisition of all GVAX assets from BioSante Pharmaceuticals, including intellectual property and cell lines. This acquisition substantially expands Aduro’s immunotherapy portfolio and strengthens its competitive position in the field.
News For BPAX From The Last 14 Days
Check below for free stories on BPAX the last two weeks.
